03 April 2025
Coulter Partners places seasoned biopharmaceutical industry executives to Altimmune Board of Directors
Coulter Partners successfully completed a search assignment for Altimmune Inc. (Nasdaq: ALT), and is pleased to announce the placement of biopharmaceutical industry executives Teri Lawver and Jerry Durso to its Board of Directors.
Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications.
Commenting on the search work with Coulter Partners, Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune, said:
“Coulter Partners’ deep life sciences expertise and proactive approach helped us secure top-tier talent. We value our partnership and look forward to continuing our collaboration.”
Related
-
Events
BIA Gala Dinner 2027
28 January 2027
-
Company News
Joe Coulter recognized by AESC for outstanding service
17 November 2026
-
Company News
Coulter Partners co-hosts UK HealthTech Super Connector event at Hale House
23 June 2026
-
Company News
Closing Q1 with momentum: The Health & Tech Collective arrives in Paris
31 March 2026